Served as co-lead counsel and secured a $51 million settlement on behalf of end-payor plaintiffs against AstraZeneca
Plaintiff(s):
End-payor plaintiffs of Seroquel XR
Case type / claims:
Antitrust class action alleging violations of Sections 1 and 2 of the Sherman Act and state antitrust laws through anticompetitive agreements that allocated markets, restricted output and delayed generic competition.
Defendant(s):
AstraZeneca, Handa Pharmaceuticals and Par Pharmaceutical
Jurisdiction:
U.S. District Court for the District of Delaware
Year:
2025
Outcome:
- Grant & Eisenhofer secured a $51 million settlement on behalf of end-payor plaintiffs.
- Case exposed unlawful agreements that preserved AstraZeneca’s monopoly and inflated prescription costs.
